Login / Signup
CCL7 Chemokine Is a Marker but Not a Therapeutic Target of Acute Kidney Injury.
Audrey Casemayou
Alexis Piedrafita
Rémi Engel
Guylène Feuillet
Melinda Alves
Ivan Tack
Julie Klein
Marie Buleon
Joost P Schanstra
Stanislas Faguer
Published in:
Nephron (2024)
Despite strong induction of CCL7 after AKI, CCL7 deficiency does not prevent AKI and the transition toward kidney fibrosis and should probably not be further explored as a potential target to prevent or treat AKI.
Keyphrases
</>
acute kidney injury
liver fibrosis
cardiac surgery
liver injury
drug induced
replacement therapy
risk assessment
smoking cessation